A Multi-Centre Non-Interventional Study to Assess the Tolerability and Effectiveness of Extended-Release Tacrolimus (LCPT) in De Novo Liver Transplant Patients
Open Access
- 28 March 2023
- journal article
- research article
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 12 (7) , 2537
Abstract
Background: Available tacrolimus formulations exhibit substantial inter- and intra-individual variability in absorption and metabolism. The present non-interventional cohort study aimed to assess the tolerability and effectiveness of the once-daily tacrolimus formulation, LCPT, in hepatic allograft recipients in real life. Materials and methods: This study was conducted in Austria and the Czech Republic between July 2016 and August 2019. Patients aged ≥ 18 years old received LCPT per the approved label and local clinical routine. All the participants provided informed consent. Patients newly treated with tacrolimus (de novo) directly after transplantation were observed for six months. The relevant clinical variables were tacrolimus trough level (TL), total daily dose (TDD), number of dose adjustments, kidney and liver function, and tolerability. Results: Of the 70 analyzed patients, 72.9% were male and 85.7% were aged < 65 years old. The mean (SD) time to achieve tacrolimus target TL was 6.4 (4.6) days after 4.4 (4.0) dose adjustments; thereafter, TL remained stable throughout observation at approximately 8 ng/mL. The LCPT TDD at initiation was 8 mg and decreased by a median of 41.4% to 5 mg at 6 months. Liver function continuously improved, and kidney function remained stable. LCPT was well tolerated with 24 adverse events in eight patients (17 related to immunosuppression, mostly mild renal insufficiency, and hematological adverse events); two serious unrelated adverse events were reported (atrial flutter and liver dysfunction). Conclusions: TL was rapidly attained with few dose adaptations after LCPT initiation in de novo liver transplant patients. Liver function rapidly improved, whereas kidney function remained normal. LCPT was well-tolerated in this population.Keywords
Funding Information
- Chiesi Pharmaceuticals GmbH
This publication has 17 references indexed in Scilit:
- Mycophenolic acid versus azathioprine as primary immunosuppression for kidney transplant recipientsCochrane Database of Systematic Reviews, 2015
- Tacrolimus Prolonged Release (Envarsus®): A Review of Its Use in Kidney and Liver Transplant RecipientsDrugs, 2015
- Once-daily LCP-Tacro MeltDose tacrolimus for the prophylaxis of organ rejection in kidney and liver transplantationsExpert Review of Clinical Immunology, 2014
- Conversion from twice daily tacrolimus capsules to once daily extended-release tacrolimus (LCP-Tacro): Phase 2 trial of stable liver transplant recipientsLiver Transplantation, 2014
- Conversion From Twice-Daily Tacrolimus Capsules to Once-Daily Extended-Release Tacrolimus (LCPT)Transplantation, 2013
- Opportunities to Optimize Tacrolimus Therapy in Solid Organ Transplantation: Report of the European Consensus ConferenceTherapeutic Drug Monitoring, 2009
- The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studiesThe Lancet, 2007
- Under-Reporting of Adverse Drug ReactionsDrug Safety, 2006
- Mode of Action of Tacrolimus (FK506): Molecular and Cellular MechanismsTherapeutic Drug Monitoring, 1995
- Clinical Pharmacokinetics of TacrolimusClinical Pharmacokinetics, 1995